Although all blood cells are derived from hematopoietic stem cells, the regulation of this production system is only partially understood. Negative feedback control mediated by erythropoietin and thrombopoietin regulates erythrocyte and platelet production, respectively, but the regulation of leukocyte levels is less well understood. The local regulatory mechanisms within the hematopoietic stem cells are also not well characterized at this point. Because of their dynamic character, cyclical neutropenia and other periodic hematological disorders offer a rare opportunity to more fully understand the nature of these regulatory processes. We review the salient clinical and laboratory features of cyclical neutropenia (and the less common disorders periodic chronic myelogenous leukemia, periodic auto-immune hemolytic anemia, polycythemia vera, aplastic anemia, and cyclical thrombocytopenia) and the insight into these diseases afforded by mathematical modeling. We argue that the available evidence indicates that the locus of the defect in most of these dynamic diseases is at the stem cell level (auto-immune hemolytic anemia and cyclical thrombocytopenia seem to be the exceptions). Abnormal responses to growth factors or accelerated cell loss through apoptosis may play an important role in the genesis of these disorders.

© 1998 by The American Society of Hematology.

MATURE BLOOD CELLS and recognizable precursors in the bone marrow ultimately derive from a small population of morphologically undifferentiated cells, the hemopoietic stem cells (HSC), which have a high proliferative potential and sustain hematopoiesis throughout life (Fig 1). The earliest HSC are totipotent and have a high self-renewal capacity.1-3These qualities are progressively lost as the stem cells differentiate. Their progeny, the progenitor cells, or colony-forming units (CFUs), are committed to one cell lineage. They proliferate and mature to form large colonies of erythrocytes, granulocytes, monocytes, or megakaryocytes. The growth of CFUs in vitro depends on lineage-specific growth factors, such as erythropoietin (EPO), thrombopoietin (TPO), granulocyte colony-stimulating factor (G-CSF), monocyte colony-stimulating factor (M-CSF), and granulocyte-monocyte colony-stimulating factor (GM-CSF).

Fig. 1.

The architecture and control of hematopoiesis. This figure gives a schematic representation of the architecture and control of platelet (P), red blood cell (RBC), and monocyte (M) and granulocyte (G) (including neutrophil, basophil, and eosinophil) production. Various presumptive control loops mediated by TPO, EPO, and G-CSF are indicated, as well as a local regulatory (LR) loop within the totipotent HSC population. CFU (BFU) refers to the various colony (burst) forming units (Meg, megakaryocyte; Mix, mixed; E, erythroid; G/M, granulocyte/monocyte) that are the in vitro analogs of the in vivo committed stem cells (CSC).

Fig. 1.

The architecture and control of hematopoiesis. This figure gives a schematic representation of the architecture and control of platelet (P), red blood cell (RBC), and monocyte (M) and granulocyte (G) (including neutrophil, basophil, and eosinophil) production. Various presumptive control loops mediated by TPO, EPO, and G-CSF are indicated, as well as a local regulatory (LR) loop within the totipotent HSC population. CFU (BFU) refers to the various colony (burst) forming units (Meg, megakaryocyte; Mix, mixed; E, erythroid; G/M, granulocyte/monocyte) that are the in vitro analogs of the in vivo committed stem cells (CSC).

Close modal

EPO ajusts erythropoiesis to the demand for O2 in the body. A decrease in tissue pO2 levels (in response to any one of a number of factors) leads to an increase in the renal production of EPO. This, in turn, leads to an increased cellular production by the primitive erythroid precursors (colony-forming units-erythroid [CFU-E]) and, ultimately, to an increase in the erythrocyte mass and hence the tissue pO2 levels. This increased cellular production triggered by EPO is due, at least in part, to an inhibition of preprogrammed cell death (apoptosis)4 5 in the CFU-E and their immediate progeny. Thus, EPO mediates a negative feedback such that an increase (decrease) in the erythrocyte mass leads to a decrease (increase) in erythrocyte production.

The mechanisms regulating granulopoiesis are not as well understood. G-CSF, the primary controlling agent of granulopoiesis, is a completely sequenced high molecular weight molecule6 produced by a number of tissues (fibroblasts, endothelial, and epithelial) and circulating cells (monocytes). G-CSF is absolutely essential for the growth of the granulocytic progenitor cells colony-forming units-granulocyte (CFU-G) in vitro.7 CFU-G colony growth is a sigmoidally increasing function of increasing G-CSF concentration.8,9 One of the modes of action of G-CSF, along with several other cytokines, is to decrease apoptosis.7,10-12 Additionally, there is a clear shorting of the neutrophil maturation time under the action of G-CSF.13 

The important role of G-CSF for the in vivo control of granulopoiesis was demonstrated by Lieschke et al.14 They showed that mice lacking G-CSF (due to an ablation of the G-CSF gene in embryonal stem cells) have pronounced neutropenia and reduction of the marrow granulocyte precursor cells by a factor of 50%. The administration of exogenous G-CSF corrects the neutropenia in 1 day and restores the marrow composition to that typical of a normal wild-type mouse within 4 days. G-CSF also rapidly corrects neutropenia of diverse causes in humans15-20 and other mammals.21-23 

Several studies have shown an inverse relation between circulating neutrophil density and serum levels of G-CSF.24-27 Coupled with the in vivo dependency of granulopoiesis on G-CSF, this inverse relationship suggests that the neutrophils would regulate their own production through a negative feedback, as is the case with erythrocytes, in which an increase (decrease) in the number of circulating neutrophils would induce a decrease (increase) in the production of neutrophils through the adjustement of G-CSF levels. Although mature neutrophils bear receptors for G-CSF and for GM-CSF, the role of these receptors in governing neutrophil production is not yet known.

The regulation of thrombopoiesis presumably involves similar negative feedback loops. Megakaryopoiesis can be separated in two processes: the proliferation and differentiation of megakaryocytic progenitor cells, and the complex process of maturation of precursor cells, which includes a variable number of endomitotic nuclear divisions, cytoplasmic growth and maturation, and the development of platelet-specific structures.

Until recently, the regulation of megakaryopoiesis was thought to include two separated control mechanisms28,29: first, a regulatory loop mediated by a megakaryocte colony stimulating antigen (Meg-CSA) responding to megakaryocyte demand and acting on the proliferation of colony-forming unit-megakaryocte (CFU-Meg); second, a thrombocytopenia-activated control of the maturation of megakaryocytes, mediated by TPO. Several growth factors, such as interleukin-11 (IL-11), IL-6, IL-3, and GM-CSF possess either one (but not both) of these activities and promote platelet production in vivo. However, none was found to be specific to the megakaryocytic lineage.28 

A lineage-specific factor that is the ligand for Mpl receptor has been cloned recently that has both Meg-CSA and TPO activity.30Plasma TPO levels are increased in thrombocytopenic patients.31 Administration of TPO to nonhuman primates induces up to sixfold to sevenfold increases in the platelet counts.31,32 It is now thought that the Mpl ligand mediates a negative feedback loop regulating platelet production.33 

There are more than 15 other cytokines acting on hematopoiesis,6 with broad, redundant actions.6,34 In vitro studies have shown that IL-3 and stem cell factor (SCF; Kit ligand) are involved with the survival of HSC, whereas IL-6, IL-11, IL-12, and G-CSF have synergestic effects on the entry into cycling of dormant HSC.17,35 In contrast to the committed progenitors, the growth of HSC in vitro thus depends on the interaction of several cytokines. The action of G-CSF on the cycling of HSC in vitro is supported by in vivo effects. Whereas suppression of G-CSF only affects granulopoiesis,14 G-CSF administration can result in multilineage recovery36 and modify the kinetics of colony-forming units-spleen (CFU-S).37 Little is known about how the self-maintenance of the HSC population is achieved. HSC are usually in a dormant state but are triggered to proliferate after transplantation into irradiated hosts.38 The specific mechanisms regulating the differentiation commitment of HSC are unknown.39Self-maintainance of HSC depends on the balance between self-renewal and differentiation. Mechanisms that could support auto-regulatory feedback control loops controlling HSC kinetics are starting to be investigated.40 

Cyclical Neutropenia (CN)

General features.

CN has been the most extensively studied periodic hematological disorder. Its hallmark is a periodic decrease in the circulating neutrophil numbers from normal values to very low values. In humans, it occurs sporadically or as an autosomal dominantly inherited disorder, and the period is typically reported to fall in the range of 19 to 21 days,41 although recent data indicate that longer periods occur in some patients.42 Our understanding of CN has been greatly aided by the discovery that the grey collie suffers from a very similar disease. The canine disorder closely resembles human CN with the exception of the period that ranges from 11 to 15 days43 and the maximum neutrophil counts, which are higher than for humans. For reviews see.41 44-50 

It is now clear that in both human CN42,51-53 and the grey collie,43 54 there is not only a periodic decrease in the circulating neutrophil levels, but also a corresponding oscillation of platelets, often the monocytes and eosinophils and occasionally the reticulocytes and lymphocytes (Fig 2A). The monocyte, eosinophil, platelet, and reticulocyte oscillations are generally from normal to high levels, in contrast to the neutrophils, which oscillate from near normal to extremely low levels. Often (but not always), the period of the oscillation in these other cell lines is the same as the period in the neutrophils.

Fig. 2.

Representative patterns of circulating cell levels in four periodic hematological disorders considered in this review. (A) CN,54 (B) PV,55 (C) AA,56 and (D) periodic CML.57 The density scales are neutrophils, 103 cells/μL; white blood cells, 104cells/μL; platelets, 105 cells/μL; reticulocytes, 104 cells/μL; and Hb, g/dL.

Fig. 2.

Representative patterns of circulating cell levels in four periodic hematological disorders considered in this review. (A) CN,54 (B) PV,55 (C) AA,56 and (D) periodic CML.57 The density scales are neutrophils, 103 cells/μL; white blood cells, 104cells/μL; platelets, 105 cells/μL; reticulocytes, 104 cells/μL; and Hb, g/dL.

Close modal

The clinical criteria for a diagnosis of CN have varied widely, although the criteria used by Dale et al58 are widely accepted. These criteria are that a patient must display an absolute neutrophil count (ANC) less than 0.5 × 109/L at least 3 to 5 consecutive days per cycle for each of three regularly spaced cycles. Usually, this requires blood cell counts three times per week for 6 to 8 weeks. Most patients will also have significant symptoms (malaise and anorexia) and signs (eg, fever, mouth ulcers, and lymphoadenopathy) during their neutropenic periods. Sometimes it is difficult to make the diagnosis with certainty. Using periodogram analysis, some patients classified as having CN do not in fact display any significant periodicity, whereas other patients classified with either congenital or idiopathic neutropenia do display significant cycling.42 

Origin.

Transplantation studies show that the origin of the defect in CN is resident in one of the stem cell populations of the bone marrow.59-64 Studies of bone marrow cellularity throughout a complete cycle in humans with CN show that there is an orderly cell density wave that proceeds successively through the myeloblasts, promyelocytes, and myelocytes and then enters the maturation compartment before being manifested in the circulation.54,65 Further studies have shown that this wave extends back into the CFU-G,66 CFU-E,67-70 as well as in the burst-forming unit-erythroid (BFU-E) and colony-forming unit–granulocyte-macrophage (CFU-GM),69 71suggesting that it may originate in the totipotent HSC populations.

Studies in the grey collie9,72 and in humans8,73 show that the responsiveness of granulocyte committed progenitor cells to G-CSF is greatly attenuated in CN compared with normal. Patients also differ from normal in their requirements for GM-CSF but not for IL-3.73 

In CN, the levels of colony-stimulating activity (CSA-related to G-CSF) fluctuate inversely with the circulating neutrophil levels and in phase with the peak in monocyte numbers.74-76 EPO levels oscillate approximately in phase with the reticulocyte oscillation.75 Dunn et al77 have also shown a periodic stimulation/repression of CFU-S (the HSC) by conditioned media derived from cyclic neutropenic marrow. It is unclear if these correlations and inverse correlations between levels of circulating cells and putative humoral regulators are related to the cause of CN or are simply a secondary manifestation of some other defect.

Effect of phlebotomy and hypertransfusion.

The effect of bleeding and/or hypertransfusion on the hematological status of grey collies gives interesting results.78 In the untreated grey collie, EPO levels cycle out of phase with the reticulocytes and virtually in phase with the neutrophil counts. After phlebotomy (bleeding of between 10% and 20% of the blood volume), the cycles in the neutrophils and reticulocytes continue as they had before the procedure, and there is no change in the relative phase between the cycles of the two cell types. Hypertransfusion (with homologous red blood cells) completely eliminates the reticulocyte cycling (as long as the hematocrit level remained elevated), but has no discernible effect on the neutrophil cycle. Most significantly, when the hematocrit level decreases back to normal levels and the reticulocyte cycle returns, the phase relation between the neutrophils and the reticulocytes is the same as before the hypertransfusion. These observations suggest that the source of the oscillations in CN is relatively insensitive to any feedback regulators involved in peripheral neutrophil and erythrocyte control, whose levels would be modified with the alteration of the density of circulating cells, and is consistent with a relatively autonomous oscillation in the HSC (see “Models of the Autoregulatory Control of HSC” below).

Effect of cytokine and lithium therapy.

In both the grey collie72,79 and in humans with CN,80-82 administration of G-CSF leads to an increase in the mean value of the peripheral neutrophil counts by a factor of as much as 10 to 20 and is associated with a clear improvement of the clinical symptoms. However, G-CSF does not obliterate the cycling in humans, but rather induces an increase in the amplitude of the oscillations and a decrease in the period of the oscillations in all the cell lineages, from 21 to 14 days.80 In human and canine CN, GM-CSF leads to an increase in neutrophil count by a factor of between 1.5 and 3.5, which is much less than achieved by G-CSF. In one report, CM-CSF obliterated cycling.82 Although recombinant canine stem cell factor (rc-SCF) does not cause neutrophillia in grey collies, it does obliterate the oscillations of CN. Lithium therapy in grey collies69,83 has uniformly yielded an elimination of the severe neutropenic phases and a diminution in the amplitude of the oscillations without any apparent change in the period of the oscillation. In humans, there are variable results with lithium,84,85 and the largest study showed lack of efficacy and toxicity problems.86 

Other Periodic Hematological Disorders Associated With Bone Marrow Defects

Periodic chronic myelogenous leukemia (CML).

CML is a hematopoietic stem cell disease characterized by granulocytosis and splenomegaly.87 In 90% of the cases, the hematopoietic cells contain a translocation between chromosomes 9 and 22 that leads to the shortening of chromosome 22, refered to as the Philadelphia (Ph) chromosome. The disease is acquired and results from the malignant transformation of a single pluripotential stem cell, as shown by the presence of a single G-6PD isoenzyme in the red blood cells, neutrophils, eosinophils, basophils, monocytes, and platelets in women with CML who are heterozygotes for isoenzymes A and B.88 The leukocyte count is greater than 100 × 109/L in 50% of the cases and it increases progressively in untreated patients. The platelet and reticulocyte counts can also be mildly elevated. In most cases, the disease eventually develops into acute leukemia.

Morley et al89 was the first to describe oscillations in the leukocyte count of CML patients in 1967. Several other cases of cyclic leukocytosis in CML have now been reported.57,90-104The leukocyte count usually cycles with an amplitude of 30 to 200 × 109 cells/L and with periods ranging from approximately 30 to 100 days. Oscillations of other blood elements in association with CML have been observed. The platelets and sometimes the reticulocytes then oscillate with the same period as the leukocytes, around normal or elevated numbers. There have been no specific studies of hematopoiesis in patients with periodic CML. There is also a report of one patient with periodic acute myelogenous leukemia.97 

Polycythemia vera (PV) and aplastic anemia (AA).

PV is characterized by an increased and uncontrolled proliferation of all the hematopoietic progenitors and it involves, like CML, the transformation of a single pluripotential stem cell. Two patients with PV were reported with cycling of the reticulocyte, platelet, and neutrophil counts in one case (Fig 2B) and cycling only of the reticulocyte counts in the other. The period of the oscillations was 27 days in the platelets, 15 days in the neutrophils, and 17 days in the reticulocytes.55 

Finally, clear oscillations in the platelet, reticulocyte, and neutrophil counts (Fig 2C) were reported in a patient diagnosed as having AA56 and in a patient with pancytopenia,105 with periods of 40 and 100 days, respectively.

Cytokine-induced cycling.

G-CSF is routinely used in a variety of clinical settings, eg, to treat chronic neutropenia or to accelerate recovery from bone marrow transplant and/or chemotherapy.58 G-CSF may induce oscillations in the level of circulating neutrophils of neutropenic individuals.42,106-108 When these oscillations arise, they always seem to be of relatively low period (on the order of 7 to 15 days), and their origin is unclear. There has also been one report of GM-CSF–induced 40-day cycling in a patient with CML after bone marrow transplant.109 

Induction of cycling by chemotherapy or radiation.

Several reports describe induction of a CN-like condition by the chemotherapeutic agent cyclophosphamide. In mongrel dogs on cyclophosphamide, the observed period was on the order of 11 to 17 days, depending on the dose of cyclophosphamide.110,111 In a human undergoing cyclophosphamide treatment, cycling with a period of 5.7 days was reported.112 Gidáli et al113observed oscillations in the granulocyte count and the reticulocyte counts with 3 weeks periodicity in mice after mild irradiation. They observed an overshooting regeneration in the reticulocytes and the thrombocytes but not in the granulocytes. Whereas the CFU-S returned to normal levels rapidly, the proliferation rate of CFU-S stayed abnormally elevated.

Five CML patients receiving hydroxyurea showed oscillations in their neutrophils, monocytes, platelets, and reticulocytes with periods in the range of 30 to 50 days.95 In one patient, an increase of the hydroxurea dose led to a cessation of the oscillations. Chikkappa et al114 report a CN-like condition (period between 15 and 25 days) in a patient with multiple myeloma after 3 years of chemotherapy.

A 89Sr-induced cyclic erythropoiesis has been described in two congenitally anemic strains of mice, W/Wv and S1/S1d.115-117W/Wv mice suffer from a defect in the HSC, and in S1/S1d mice the hematopoietic micro-environment is defective.

The induction of cycling by 89S can be understood as a response to elevated cell death (see “Models of the Autoregulatory Control of HSC” below), as can the dynamic effects of chemotherapy.

Periodic Hematological Disorders of Peripheral Origin: Auto-Immune Hemolytic Anemia (AIHA) and Cyclical Thrombocytopoiesis

Periodic AIHA is a rare form of hemolytic anemia in humans.118 Periodic AIHA, with a period of 16 to 17 days in hemoglobin and reticulocyte counts, has been induced in rabbits by using red blood cell auto-antibodies.119 

Cyclic thrombocytopenia, in which platelet counts oscillate from normal to very low values, has been observed with periods between 20 and 40 days120-136 (reviewed by Cohen and Cooney126). Although it has been claimed that oscillations could be detected in the platelet counts of normal individuals with the same range of periods,137 138 this conclusion may not be statistically justified.

In clinical reports of periodic diseases affecting hematopoiesis, oscillations have usually been observed only in the blood counts without examinations of bone marrow precursors and progenitor cells. However, even in the case of CN in which the kinetics of hematopoiesis have been extensively studied, the mechanisms responsible for the onset of periodic oscillations are still unknown. A number of mathematical models have been put forward that suggest possible mechanisms for the origin of oscillations in hematopoiesis. These models fall into two major categories. The first group identifies the origin of the oscillations with the loss of stability in peripheral control loops adjusting the production rate of blood precursors to the number of mature cells in the blood and mediated by TPO, EPO, and G-CSF (Fig 1). The second group is based on the assumption that oscillations arise in stem cell populations as a consequence of the loss of stability of auto-regulatory (local and LR) control loops (Fig 1). A few investigators have also modeled interactions between these two types of control loops (see Dunn139 and Fisher140 for reviews).

Models of the Peripheral Control of Hematopoiesis

It is well known that simple negative feedback systems, such as the erythroid control system, have a tendency to oscillate. The relative detail known about erythrocyte production control has not escaped the attention of modelers who have mathematically explored ways to explain the results of laboratory manipulations in rodents,141-147and rabbits119,148 and the nature of the human erythropoietic regulatory system in health and disease.149-152 

The control of erythropoiesis by EPO can be modeled by a single delayed differential equation describing the rate of change of RBC production as a function of the death rate of circulating erythrocytes, the rate of change of cell production after a given perturbation of the circulating RBC number, and the maturation time of erythrocyte progenitors. The transition from damped to stable oscillations, which characterizes the onset of periodic hematopoiesis, depends on the modification of one or several of these controlling parameters. In AIHA, the death rate of circulating RBC is increased, whereas the other parameters lie within normal ranges. The mathematical modeling of the control of RBC production by EPO indicates that such an increase in the destruction rate of circulating erythrocytes will induce periodic fluctuations of erythropoiesis around a low average, with periods similar to the ones observed in AIHA.153-155 From a modeling perspective, the laboratory version of rabbit AIHA is thus one of the best understood periodic hematological diseases.

Similar mathematical treatments have been applied to the control of granulopoiesis and megakaryopoiesis, even though the existence of functional peripheral feedback in these systems is still hypothetical.

A few investigators have formulated models for the regulation of thrombopoiesis138,156-159 assuming the existence of a negative feedback loop mediated by TPO. Bélair and Mackey160 specifically considered cyclical thrombocytopenia. They speculated that elevations in the random destruction rate of platelets could give rise to the characteristic patterns observed in cyclical thrombocytopenia. Although modeling results based on this assumption yielded results qualitatively consistent with the clinical data, there is still much room for further study of this problem.

Several models of granulopoiesis incorporate a peripheral negative feedback loop.161-172 In the grey collie and in CN patients, the survival of circulating neutrophils is normal.51 This finding implies that there is not a periodic elevation of the peripheral death rate of neutrophils in CN, but rather a periodic modulation of marrow cell production. An alteration of the peripheral control of granulopoiesis has been proposed as the mechanism of CN by several investigators.56,110,111 173-185 

There is experimental evidence of alterations in the kinetics of granulopoiesis in CN, ie, the modification of the distribution of maturation time and the subnormal responsiveness of granulocytic progenitors to CSF. However, recent modeling indicates that these are insufficient to account for a destabilization of the putative peripheral feedback control of granulocytopoiesis.186Moreover, the lack of effect of hypertransfusion or phlebotomy on either cycle (neutrophil or reticulocyte) strongly implies that there is not a direct role of peripheral feedback loops in the origin of the cycling in CN.

A few attempts have also been made to model periodic CML based on the peripheral control of granulopoiesis171,187,188 but are also unsatisfactory in the sense that the models have assumptions on the kinetic of granulopoiesis in CML that are now known to be biologically unrealistic.189 190 

The occurrence of oscillations in several blood elements in CN and CML strongly suggests that the oscillations are not a consequence of a lineage-specific regulatory loop but rather of regulatory mechanisms affecting all hematopoiesis. The existence of a peripheral feedback loop controlling granulopoiesis can thus not be supported by the occurence of oscillations in CN and CML.

Models of the Autoregulatory Control of HSC

Except for AIHA and cyclical thrombocytopenia, the periodic hematological disorders that have been described are characterized by the occurence of oscillations in many or all of the peripheral cellular elements (neutrophils, platelets, lymphocytes, and reticulocytes). Many have speculated that the origin of these oscillations is in the common HSC population feeding progeny into the differentiated cell lines.

Mackey191 193 proposed that there could be a loss of stability in the stem cell population independent of feedback from peripheral circulating cell types. He analyzed a mathematical model for a stem cell population in which the proportion of cells entering proliferation depends on the size of the population in G0(Fig 3). The efflux into the different commited cell lineages depends on the size of the population, which varies with the rate of proliferation and the cell death rate.

Fig. 3.

A schematic representation of the control of HSC regeneration. Proliferating phase cells include those cells in G1, S (DNA synthesis), G2, and M (mitosis), whereas the resting phase cells are in the G0 phase. Local regulatory influences are exerted via a cell number dependent variation in the rate of entry into proliferation. Differentiation into all of the comitted stem cell populations occurs from the G0population, whereas there is a loss of proliferating phase cells due to apoptosis. See Mackey191 and Milton and Mackey192 for further details.

Fig. 3.

A schematic representation of the control of HSC regeneration. Proliferating phase cells include those cells in G1, S (DNA synthesis), G2, and M (mitosis), whereas the resting phase cells are in the G0 phase. Local regulatory influences are exerted via a cell number dependent variation in the rate of entry into proliferation. Differentiation into all of the comitted stem cell populations occurs from the G0population, whereas there is a loss of proliferating phase cells due to apoptosis. See Mackey191 and Milton and Mackey192 for further details.

Close modal

Other investigators194-202 have considered the dynamics of auto-regulatory stem cell populations from a modeling perspective applied to various experimental and clinical situations. Nečas et al40 203-205 have developed such a modeling study based on experimental evidence that the number of stem cells entering proliferation is controlled by the number of DNA-synthesizing cells. Cell to cell interactions or cytokines that are essential for the growth of HSC in vitro, such as IL-3 and SCF, could be involved in the autoregulation of HSC proliferation.

Because of the delay in the autoregulation loop, due to the time necessary for replicating cells to go through the S phase and the mitotic phase, this system has a tendency to oscillate. In normal conditions it is assumed that the population does not oscillate. Mackey191 showed that an abnormally large irreversible cell loss within the proliferating compartment, which can represent either apoptosis or other cell death, would induce oscillations of the number of stem cells. Figure 4 shows the variations in the amplitude and the period of the oscillations predicted by the model as the apoptotic rate is increased. An increase in the apoptotic rate of HSC also induces a decrease in the average efflux from the HSC to all the cell lineages. This is consistent with the occurence of oscillations in all the blood elements in some patients with AA, in which all the blood cell counts are low, as well as the oscillations observed in several cell lineages after chemotherapy or radiation. The range of periods obtained by Mackey depends largely on the rate of irreversible cell loss and on the cell cycle time delay. Depending on the value of these parameters, the period can vary from 16 to 43 days in humans and from 9 to 26 days in dogs. In most periodic hematological disorders, large differences consistent with these values have been observed in the period of the oscillations between different individuals.

Fig. 4.

(A) Schematic representation of the effects of increasing apoptotic rate on the HSC dynamics, as predicted from the model proposed previously.191,192 The diagram shows the effect of administering the same dose of 89Sr to W/Wv and S1/S1d mice on the amplitude and the period of the oscillations. The dashed lines show the onset and the end of oscillations as the apoptotic rate increases. (B) Computer simulations of the normalized HSC efflux predicted191 for increasing apoptotic rates (from I to V). As the apoptotic rate is increased, the period of the oscillations increases and the amplitude increases and decreases consecutively.

Fig. 4.

(A) Schematic representation of the effects of increasing apoptotic rate on the HSC dynamics, as predicted from the model proposed previously.191,192 The diagram shows the effect of administering the same dose of 89Sr to W/Wv and S1/S1d mice on the amplitude and the period of the oscillations. The dashed lines show the onset and the end of oscillations as the apoptotic rate increases. (B) Computer simulations of the normalized HSC efflux predicted191 for increasing apoptotic rates (from I to V). As the apoptotic rate is increased, the period of the oscillations increases and the amplitude increases and decreases consecutively.

Close modal

The model also gives a plausible explanation for the 89Sr induction of cyclic erythropoiesis in the two congenitally anemic strains of mice, W/Wv and S1/S1d (Fig 4). Assume that the difference between W/Wv and S1/S1dmice is solely related to differences in the rate of apoptosis.206. (The observation that S1/S1d mice are more refractory to erythropoietin than W/Wv mice suggests that the apoptotic rate is higher in S1/S1d.) The results of Mackey191 predict that a higher rate of apoptosis would increase the likelihood that an oscillation in erythrocyte number occurs. Indeed, in contrast to W/Wv mice, approximately 40% of S1/S1d mice have spontaneous oscillations in their hematocrit.115,116 In both strains of mice, a single dose of 89Sr is sufficient to increase apoptosis into a range associated with oscillations in erythrocyte number. Because the apoptotic rate for the S1/S1d mice is greater than that for W/Wv mice before 89Sr, it is reasonable to expect that it will also be higher after administration of equal doses of 89Sr to both strains of mice. As predicted, the period of the oscillation is longer, the amplitude is larger, and the mean hematocrit is lower for S1/S1d mice than they are for W/Wv mice.192 

The Particular Cases of CN and CML

Destabilization of an early HSC population resulting in oscillations with a large range of periods in all the blood elements after radiation or chemotherapy and in AA may also be at the origin of the oscillations observed in CN and CML. Modification of any of the parameters in the model described in Mackey191 (Fig 3) can potentially induce the onset of oscillations.

Even though all the blood elements are often oscillating in periodic CML and CN, the defect in these two disorders primarily affects granulopoiesis. The abnormal responsiveness of CFU-G explains the low ANC levels in CN, which may induce an alteration in the cytokine levels. The fact that G-CSF is the only cytokine shown to alter the period of the oscillations in all the blood elements shows that it plays a crucial role in the mechanism at the origin of the oscillations in CN. The finding that G-CSF not only regulates granulopoiesis, but also affects the kinetics of early HSC suggests that its effect on the oscillations in CN may be mediated through the modification of HSC dynamics. In vitro studies of the effect of G-CSF suggest that it increases the rate of entry into cycling, which is likely to destabilize the steady state while increasing the average size of the population. This is consistent with the mildly elevated platelet, monocyte, and lymphocyte counts often observed in CN. Similar mechanisms may also induce the oscillations in CML.

The mechanisms underlying the complex dynamical features of CN and periodic CML will more likely be understood with the use of models that include both the local autoregulation of early stem cells and its relation with the more mature hemopoietic compartments. The multilevel effect of cytokines such as G-CSF suggests indeed that strong relationships exist between the regulation of early and late hematopoietic compartments.

This review focuses on the clinical and laboratory findings in periodic hematopoietic diseases, including CN, periodic CML, AA, PV, AIHA, and cyclical thrombocytopenia. With the exception of the latter two, the available evidence indicates a broad involvement of the entire hematopoietic system, because cycling is typically observed in more than one of the mature hematopoietic cell types.

Cycling in one or several hematopoietic cell lineages is probably much more frequent than reported and would be detected if serial blood counts were systematically performed. These observations suggest a major derangement of the dynamics of one or more of the stem cell populations such that they become unstable and generate sustained oscillations that are manifested in more than one of their progenitor lines. Mathematical modeling studies suggest that there are several ways in which the HSC dynamics can be destabilized and give rise to oscillations if they are controlled by an autoregulatory loop. The finding that lineage-specific cytokines also have an effect on early HSC regulation implies that oscillations could arise as a result of the alteration of only one compartment, such as observed in CN and CML. Analysis of the effect of the cytokines on the dynamical features of these disorders, through modeling studies, may be a key to the understanding of the nature of early hematopoiesis regulation.

Supported by the Natural Sciences and Engineering Research Council (NSERC Grant No. OGP-0036920, Canada), the National Institutes of Health (NIH Grant No. 18951, USA), Le Fonds pour la Formation de Chercheurs et l’Aide à la Recherche (FCAR Grant No. 98ER1057, Québec), and the École Normale Supérieure de Paris.

Address reprint requests to Michael C. Mackey, PhD, Departments of Physiology, Physics, and Mathematics, Center for Nonlinear Dynamics in Physiology and Medicine, McGill University, McIntyre Drummond Building, 3655 Drummond St, Montreal H3G 1Y6, Quebec, Canada.

1
Abramson
 
S
Miller
 
RG
Phillips
 
RA
The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems.
J Exp Med
145
1977
1567
2
Becker
 
A
McCulloch
 
E
Till
 
J
Cytological demonstration of the clonal nature of splenn colonies derived from transplanted mouse marrow cells.
Nature
197
1963
452
3
Lemishka
 
IR
Raulet
 
DH
Mulligan
 
RC
Developmental potential and dynamic behavior of hemopoietic stem cells.
Cell
45
1986
917
4
Adamson
 
J
The relationship of erythropoietin and iron metabolism to red blood cell production in humans.
Semin Oncol
21
1974
9
5
Silva
 
M
Grillot
 
D
Benito
 
A
Richard
 
C
Nunez
 
G
Fernandez-Luna
 
JL
Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-1 and bcl-2.
Blood
88
1996
1576
6
Metcalf
 
D
Nicola
 
NA
The Hemopoietic Colony Stimulating Factors.
1995
Cambridge
Cambridge, UK
7
Williams
 
GT
Smith
 
CA
Spooncer
 
E
Dexter
 
TM
Taylor
 
DR
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis.
Nature
353
1990
76
8
Hammond
 
WP
Chatta
 
GS
Andrews
 
RG
Dale
 
DC
Abnormal responsiveness of granulocyte committed progenitor cells in cyclic neutropenia.
Blood
79
1992
2536
9
Avalos
 
BR
Broudy
 
VC
Ceselski
 
SK
Druker
 
BJ
Griffin
 
JD
Hammond
 
WP
Abnormal response to granulocyte colony stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression.
Blood
84
1994
789
10
Koury
 
MJ
Programmed cell death (apoptosis) in hematopoiesi.
Exp Hematol
20
1992
391
11
Park
 
JR
Cytokine regulation of apoptosis in hematopoietic precursor cells.
Curr Opin Hematol
3
1996
191
12
Williams
 
GT
Smith
 
CA
Molecular regulation of apoptosis: Genetic controls on cell death.
Cell
74
1993
777
13
Price
 
TH
Chatta
 
GS
Dale
 
DC
Effect of recombinant granulocyte colony stimulating factor on neutrophil kinetics in normal young and elderly humans.
Blood
88
1996
335
14
Lieschke
 
GJ
Grail
 
D
Hodgson
 
G
Metcalf
 
D
Stanley
 
E
Cheers
 
C
Fowler
 
KJ
Basu
 
S
Zhan
 
YF
Dunn
 
AR
Mice lacking granulocyte colony stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.
Blood
84
1994
1737
15
Bronchud
 
MH
Scarffe
 
JH
Thatcher
 
N
Crowther
 
D
Souza
 
LM
Alton
 
NK
Testa
 
NG
Dexter
 
TM
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
Br J Cancer
56
1987
809
16
Layton
 
JE
Hockman
 
H
Sheridan
 
WP
Morstyn
 
G
Evidence for a novel in vivo control mechanism of granulopoiesis: Mature cell-related control of a regulatory growth factor.
Blood
74
1989
1303
17
Leary
 
AG
Zeng
 
HQ
Clark
 
SC
Ogawa
 
M
Growth factor requirements for survival in g0 and entry into the cell cycle of primitive human hemopoietic progenitors.
Proc Natl Acad Sci USA
89
1992
4013
18
Lord
 
BI
Myeloid cell kinetics in response to haemopoietic growth factors.
Clin Haematol
5
1992
533
19
Lord
 
BI
Bronchud
 
MH
Owens
 
S
Chang
 
J
Howell
 
A
Souza
 
L
Dexter
 
TM
The kinetics of human granulopoiesis following treatment with granulocyte colony stimulating factor in vivo.
Proc Natl Acad Sci USA
86
1989
9499
20
Ponchio
 
L
Conneally
 
E
Eaves
 
C
Quantitation of the quiescent fraction of long term culture initiating cells in normal human blood and marrow and the kinetics of their growth factor stimulated entry into s phase in vitro.
Blood
86
1995
3314
21
Cohen
 
AM
Zsebo
 
KM
Inoue
 
H
Hines
 
D
Boone
 
TC
Chazin
 
VR
Tsai
 
L
Ritch
 
T
Souza
 
LM
In vivo stimulation of granulopoiesis by recombinant human granulocyte colony stimulating factor.
Proc Natl Acad Sci USA
84
1987
2484
22
Lord
 
BI
Molineux
 
G
Pojda
 
Z
Souza
 
LM
Mermod
 
JJ
Dexter
 
TM
Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo.
Blood
77
1991
2154
23
Molineux
 
G
Pojda
 
Z
Dexter
 
TM
A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony stimulating factor.
Blood
75
1990
563
24
Kearns
 
CM
Wang
 
WC
Stute
 
N
Ihle
 
JN
Evans
 
WE
Disposition of recombinant human granulocyte colony stimulating factor in children with severe chronic neutropenia.
J Pediatr
123
1993
471
25
Mempel
 
K
Pietsch
 
T
Menzel
 
T
Zeidler
 
C
Welte
 
K
Increased serum levels of granulocyte colony stimulating factor in patients with severe congenital neutropenia.
Blood
77
1991
1919
26
Takatani
 
H
Soda
 
H
Fukuda
 
M
Watanabe
 
M
Kinoshita
 
A
Nakamura
 
T
Oka
 
M
Levels of recombinant human granulocyte colony stimulating factor in serum are inversely correlated with circulating neutrophil counts.
Antimicrob Agents Chemother
40
1996
988
27
Watari
 
K
Asano
 
S
Shirafuji
 
N
Kodo
 
H
Ozawa
 
K
Takaku
 
F
Kamachi
 
S
Serum granulocyte colony stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay.
Blood
73
1989
117
28
Hoffman
 
R
Regulation of megakaryocytopoiesis.
Blood
74
1989
1196
29
Mazur
 
EM
Megakaryocytopoiesis and platelet production: A review.
Exp Hematol
15
1987
340
30
Wendling
 
F
Maraskovski
 
E
Debill
 
N
Florinda
 
C
Teepe
 
M
Titeux
 
M
Methia
 
N
Breton-Gorius
 
J
Cosman
 
D
Vainchenker
 
W
c-mpl ligand is a humoral regulator of megakaryopoiesis.
Nature
369
1994
571
31
Nichol
 
JL
Hokom
 
MM
Hornkohl
 
A
Sheridan
 
WP
Ohashi
 
H
Kato
 
T
Li
 
YS
Bartley
 
TD
Choi
 
E
Bogenberger
 
J
Megakaryocyte growth and development factor: Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy induced thrombocytopenia.
J Clin Invest
95
1995
2973
32
Kaushansky
 
K
Thrombopoietin: The primary regulator of platelet production.
Blood
86
1995
419
33
Sheridan
 
WP
Kuter
 
DJ
Mechanism of action and clinical trials of mpl ligand.
Curr Opin Hematol
4
1997
312
34
Sachs
 
L
Lotem
 
J
The network of hematopoietic cytokines.
Proc Soc Exp Biol Med
206
1994
170
35
Ogawa
 
M
Hematopoiesis.
J Allergy Clin Immunol
94
1994
645
36
Sonoda
 
Y
Yashige
 
H
Fujii
 
H
Tsuda
 
S
Maekawa
 
T
Misawa
 
S
Abe
 
T
Bilineage response in refractory aplastic anemia patients following long-term administration of recombinant human granulocyte colony-stimulating factor.
Eur J Haematol
48
1992
41
37
Mizoguchi
 
H
Suda
 
T
Miura
 
Y
Kubota
 
K
Takahu
 
F
Hemopoietic stem cells in nude mice transplanted with colony-stimulating-factor-producing tumors.
Exp Hematol
10
1982
874
38
Necas
 
E
Triggering of stem cell (cfu-s) proliferation after transplantation into irradiated hosts.
Exp Hematol
20
1992
1146
39
Ogawa
 
M
Differentiation and proliferation of hematopoietic stem cells.
Blood
81
1993
2844
40
Necas
 
E
Znojil
 
V
Vacha
 
J
Stem cell number versus the fraction synthesizing dna.
Exp Hematol
16
1988
231
41
Dale
 
DC
Hammond
 
WP
Cyclic neutropenia: A clinical review.
Blood Rev
2
1988
178
42
Haurie C, Mackey MC, Dale DC: Dynamics in congenital, idiopathic, and cyclical neutropenia before and after treatment with G-CSF. Exp Hematol (in press)
43
Haurie C, Person R, Mackey MC, Dale DC: Neutrophil dynamics in the grey collie: Modification of cyclical neutropenia by G-CSF. (manuscript in preparation)
44
Dale
 
DC
Wolff
 
SM
Cyclic neutropenia in man and gray collie dogs.
Birth Defects
8
1972
59
45
Jones
 
JB
Lange
 
RD
Cyclic hematopoiesis: Animal models.
Immunol Hematol Res Monogr
1
1983
33
46
Lange
 
RD
Cyclic hematopoiesis: Human cyclic neutropenia.
Exp Hematol
11
1983
435
47
Lange
 
RD
Jones
 
JB
Cyclic hematopoiesis: Animal models.
Exp Hematol
11
1983
571
48
Page
 
AR
Good
 
RA
Studies on cyclic neutropenia.
Am J Dis Child
94
1957
623
49
Quesenberry
 
PJ
Cyclic hematopoiesis: Disorders of primitive hematopoietic stem cells.
Immunol Hematol Res Monogr
1
1983
2
50
Wright
 
DG
Dale
 
DC
Fauci
 
AS
Wolff
 
SM
Human cyclic neutropenia: Clinical review and long term follow up of patients.
Medicine
60
1981
1
51
Dale
 
DC
Ward
 
SB
Kimball
 
JR
Wolff
 
SM
Studies of neutrophil production and turnover in grey collie dogs with cyclic neutropenia.
J Clin Invest
51
1972
2190
52
Dale
 
DC
Alling
 
DW
Wolff
 
SW
Cyclic hematopoiesis: The mechanism of cyclic neutropenia in grey collie dogs.
J Clin Invest
51
1972
2197
53
Hoffman
 
HJ
Guerry
 
D
Dale
 
DC
Analysis of cyclic neutropenia using digital band-pass filtering techniques.
J Interdisciplinary Cycle Res
5
1974
1
54
Guerry
 
D
Dale
 
DC
Omine
 
M
Perry
 
S
Wolff
 
SM
Periodic hematopoiesis in human cyclic neutropenia.
J Clin Invest
52
1973
3220
55
Morley
 
A
Blood-cell cycles in polycythaemia vera.
Aust Ann Med
18
1969
124
56
Morley
 
A
Cyclic hemopoiesis and feedback control.
Blood Cells
5
1979
283
57
Chikkappa
 
G
Burlington
 
H
Borner
 
G
Chanana
 
AD
Cronkite
 
EP
Ohl
 
S
Pavelec
 
M
Robertso
 
JS
Periodic oscillation of blood leukocytes, platelets, and reticulocytes in a patient with chronic myelocytic leukemia.
Blood
47
1976
1023
58
Dale
 
DC
Bonilla
 
MA
Davis
 
MW
Nakanishi
 
AM
Hammond
 
WP
Kurtzberg
 
J
Wang
 
W
Jakubowski
 
A
Winton
 
E
Lalezari
 
P
Robinson
 
W
Glaspy
 
JA
Emerson
 
S
Gabrilove
 
J
Vincent
 
M
Boxer
 
LA
A randomized controlled phase III trial of recombinant human granulocyte colony stimulating factor (filgrastim) for treatment of severe chronic neutropenia.
Blood
81
1993
2496
59
Dale
 
DC
Graw
 
RG
Transplantation of allogenic bone marrow in canine cyclic neutropenia.
Science
183
1974
83
60
Jones
 
JB
Lange
 
RD
Yang
 
TJ
Vodopick
 
H
Jones
 
ES
Canine cyclic neutropenia: Erythropoietin and platelet cycles after bone marrow transplantation.
Blood
45
1975
213
61
Jones
 
JB
Yang
 
TJ
Dale
 
JB
Lange
 
RD
Canine cyclic haematopoiesis: Marrow transplantation between littermates.
Br J Haematol
30
1975
215
62
Weiden
 
PL
Robinett
 
B
Graham
 
TC
Adamson
 
J
Storb
 
R
Canine cyclic neutropenia.
J Clin Invest
53
1974
950
63
Krance
 
RA
Spruce
 
WE
Forman
 
SJ
Rosen
 
RB
Hecht
 
T
Hammond
 
WP
Blume
 
G
Human cyclic neutropenia transferred by allogeneic bone marrow grafting.
Blood
60
1982
1263
64
Patt
 
HM
Lund
 
JE
Maloney
 
MA
Cyclic hematopoiesis in grey collie dogs: A stem-cell problem.
Blood
42
1973
873
65
Brandt
 
L
Forssman
 
O
Mitelman
 
R
Odeberg
 
H
Oloffson
 
T
Olson
 
I
Svensson
 
B
Cell production and cell function in human cyclic neutropenia.
Scand J Haematol
15
1975
228
66
Jacobsen
 
N
Broxmeyer
 
HE
Oscillations of granulocytic and megakaryocytic progenitor cell populations in cyclic neutropenia in man.
Scand J Haematol
23
1979
33
67
Dunn
 
CDR
Jones
 
JB
Lange
 
RD
Progenitor cells in canine cyclic hematopoiesis.
Blood
50
1977
1111
68
Dunn
 
CDR
Jolly
 
JD
Jones
 
JB
Lange
 
RD
Erythroid colony formation in vitro from the marrow of dogs with cyclic hematopoiesis: Interrelationship of progenitor cells.
Exp Hematol
6
1978
701
69
Hammond
 
WP
Dale
 
DC
Cyclic hematopoiesis: Effects of lithium on colony forming cells and colony stimulating activity in grey collie dogs.
Blood
59
1982
179
70
Jones
 
JB
Jolly
 
JD
Canine cyclic haematopoiesis: Bone marrow adherent cell influence of CFU-C formation.
Br J Haematol
50
1982
607
71
Abkowitz
 
JL
Holly
 
RD
Hammond
 
WP
Cyclic hematopoiesis in dogs: Studies of erythroid burst forming cells confirm an early stem cell defect.
Exp Hematol
16
1988
941
72
Lothrop
 
CD
Warren
 
DJ
Souza
 
LM
Jones
 
JB
Moore
 
MAS
Correction of canine cyclic hematopoiesis with recombinant human granulocyte colony-stimulating factor.
Blood
72
1988
1324
73
Wright
 
DG
LaRussa
 
VF
Salvado
 
AJ
Knight
 
RD
Abnormal responses of myeloid progenitor cells to granulocyte macrophage colony stimulating factor in human cyclic neutropenia.
J Clin Invest
83
1989
1414
74
Dale
 
DD
Brown
 
C
Carbone
 
P
Wolff
 
SM
Cyclic urinary leukopoietic activity in gray collie dogs.
Science
173
1971
152
75
Guerry
 
D
Adamson
 
DJW
Dale
 
C
Wolff
 
SM
Human cyclic neutropenia: Urinary colony-stimulating factor and erythropoietin levels.
Blood
44
1974
257
76
Moore
 
M
Spitzer
 
G
Metcalf
 
D
Penington
 
DG
Monocyte production of colony stimulating factor in familial cyclic neutropenia.
Br J Haematol
27
1974
47
77
Dunn
 
CDR
Jones
 
JB
Lange
 
RD
Wright
 
EG
Moore
 
MAS
Production of presumptive humoral haematopoietic regulators in canine cyclic haematopoiesis.
Cell Tissue Kinet
15
1982
1
78
Adamson
 
JW
Dale
 
DC
Elin
 
RJ
Hematopoiesis in the grey collie dog: Studies of the regulation of erythropoiesis.
J Clin Invest
54
1974
965
79
Hammond
 
WP
Boone
 
TC
Donahue
 
RE
Souza
 
LM
Dale
 
DC
Comparison of treatment of canine cyclic hematopoiesis with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF, interleukin-3, and canine G-CSF.
Blood
76
1990
523
80
Hammond
 
WP
Price
 
TH
Souza
 
LM
Dale
 
DC
Treatment of cyclic neutropenia with granulocyte colony stimulating factor.
N Engl J Med
320
1989
1306
81
Migliaccio
 
AR
Migliaccio
 
G
Dale
 
DC
Hammond
 
WP
Hematopoietic progenitors in cyclic neutropenia: Effect of granulocyte colony stimulating factor in vivo.
Blood
75
1990
1951
82
Wright
 
DG
Kenney
 
RF
Oette
 
DH
LaRussa
 
VF
Boxer
 
LA
Malech
 
HL
Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia.
Blood
84
1994
1257
83
Hammond
 
WP
Dale
 
DC
Lithium therapy of canine cyclic hematopoiesis.
Blood
55
1980
26
84
Fehr
 
J
von Schulthess
 
GK
Dahinde
 
C
Cyclic neutropenia: Amplification of granulocyte oscillations by lithium and long-term suppression of cycling by plasmapheresis.
Blood
62
1983
320
85
Verma
 
DS
Spitzer
 
G
Zander
 
AR
Dicke
 
KA
McCredie
 
KB
Cyclic neutropenia and T lymphocyte suppression of granulopoiesis: Abrogation of the neutropenic cycles by lithium carbonat.
Leuk Res
6
1982
567
86
Hammond
 
WP
Berman
 
B
Wright
 
DG
Dale
 
DC
Lithium is an ineffective therapy for human cyclic hematopoiesis.
Blood
61
1983
1024
87
Grignani
 
F
Chronic myelogenous leukemia.
Crit Rev Oncol Hematol
4
1985
31
88
Fialkow
 
PJ
Jacobson
 
RJ
Papayannopoulou
 
T
Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage.
Am J Med
63
1977
125
89
Morley
 
AA
Baikie
 
AG
Galton
 
DAG
Cyclic leukocytosis as evidence for retention of normal homeostatic control in chronic granulocytic leukaemia.
Lancet
2
1967
1320
90
Delobel
 
J
Charbord
 
P
Passa
 
P
Bernard
 
J
Evolution cyclique spontanée de la leucocytose dans un cas de leucémie myéloide chronique.
Nouv Rev Franc Hématol
13
1973
221
91
Gatti
 
RA
Robinson
 
WA
Deinare
 
AS
Nesbit
 
M
Ballow
 
M
Good
 
RA
McCullough
 
JJ
Cyclic leukocytosis in chronic myelogenous leukemia.
Blood
41
1973
771
92
German
 
HJ
Smith
 
JA
Lindenbaum
 
J
Chronic intravascular coagulation associated with chronic myelocytic leukemia.
Am J Med
61
1976
547
93
Iizuka
 
Y
Horikoshi
 
A
Sekiya
 
S
Sawada
 
U
Ohshima
 
T
Amaki
 
I
Periodic fluctuation of leukocytes, platelets and reticulocytes in a case of chronic myelocytic leukemia: The relation between leukocyte counts, CFU-C colony formation, CSA and CIA.
Acta Haematol Jpn
47
1984
71
94
Inbal
 
A
Akstein
 
E
Barok
 
I
Meytes
 
D
Many
 
A
Cyclic leukocytosis and long survival in chronic myeloid leukemia.
Acta Hematol
69
1983
353
95
Kennedy
 
BJ
Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy.
Blood
35
1970
751
96
Mastrangelo
 
R
Stabile
 
A
Parenti
 
D
Segni
 
G
Spontaneous leukocyte oscillation during blastic crisis of chronic myeloid leukemia.
Cancer
33
1974
1610
97
Mastrangelo
 
R
Stabile
 
A
Parenti
 
D
Cimatti
 
G
A specific spontaneous leukocyte cycle in chronic myelogenous leukemia.
Tumori
62
1976
197
98
Meitra
 
BC
Agarwa
 
B
Cyclic oscillations in leukocyte count in chronic myeloid leukemia.
Acta Heamatol
63
1980
68
99
Olofsson
 
T
Olsson
 
I
Granulopoiesis in chronic myeloid leukemia. II. Serial cloning of blood and bone marrow cells in agar culture.
Blood
48
1976
351
100
Rodriguez
 
AR
Lutcher
 
CL
Marked cyclic leukocytosis leukopenia in chronic myelogenous leukemia.
Am J Med
60
1976
1041
101
Shadduck
 
RK
Winkelstein
 
A
Nunna
 
NG
Cyclic leukemia cell production in CML.
Cancer
29
1972
399
102
Umemura
 
T
Hirata
 
J
Kaneko
 
S
Nishimura
 
J
Motomura
 
S
Kozuru
 
M
Ibayashi
 
H
Periodical appearance of erythropoietin-independent erythropoiesis in chronic myelogenous leukemia with cyclic oscillation.
Acta Haematol
76
1986
230
103
Vodopick
 
H
Rupp
 
EM
Edwards
 
CL
Goswitt
 
GA
Beauchamp
 
JJ
Spontaneous cyclic leukocytosis and thrombocytosis in chronic granulocytic leukemia.
N Engl J Med
286
1972
284
104
Yamauchi
 
K
Ide
 
A
Spontaneous remission with cyclic leukocytosis in chronic myelogenous leukemia.
Acta Haematol
88
1992
136
105
Birgens
 
HS
Karl
 
H
Reversible adult-onset cyclic haematopoiesis with a cycle length of 100 days.
Br J Hematol
83
1993
181
106
Bonilla
 
MA
Gillio
 
AP
Kernan
 
NA
Ruggeiro
 
M
Brochstein
 
JL
Abboud
 
M
Fumagalli
 
L
Vincent
 
M
Gabrilove
 
JL
Welte
 
K
Souza
 
LM
O’Reilly
 
RJ
Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis.
N Engl J Med
320
1989
1574
107
Jakubowski
 
AA
Souza
 
L
Kelly
 
F
Fain
 
K
Budman
 
D
Moore
 
MAS
Gabrilov
 
J
Clarkson
 
B
Bonilla
 
MA
Effects of human granulocyte colony stimulating factor in a patient with idiopathic neutropenia.
N Engl J Med
320
1989
38
108
Welte
 
K
Zeidler
 
C
Reiter
 
A
Muller
 
W
Odenwald
 
E
Souza
 
L
Riehm
 
H
Differential effects of granulocyte macrophage colony stimulating factor and granulocyte colony stimulating factor in children with severe congenital neutropenia.
Blood
75
1990
1056
109
Gluckman
 
E
Socie
 
AG
Yver
 
A
Esperou
 
H
Devergie
 
A
Stern
 
A
Transient cyclic neutropenia following GM-CSF in a patient with chronic granulocytic leukemia transplanted with HLA identical T cell depleted donor bone marrow.
Bone Marrow Transplant
4
1989
591
110
Stohlman
 
F
The oscillatory nature of hemopoiesis, Stohlman F (ed): Hemopoietic Cellular Proliferation.
1969
3
Grune & Stratton
New York, NY
111
Morley
 
A
Stohlman
 
F
Cyclophosphamide induced cyclical neutropenia.
N Engl J Med
282
1970
643
112
Dale
 
DC
Alling
 
DW
Wolff
 
SM
Application of time series analysis to serial blood neutrophil counts in normal individuals and patients receiving cyclophosphamide.
Br J Haematol
24
1973
57
113
Gidáli
 
J
István
 
E
Fehér
 
I
Long-term perturbation of hemopoiesis after moderate damage to stem cells.
Exp Hemaetol
13
1985
647
114
Chikkappa
 
G
Chanana
 
AD
Chandra
 
P
Cronkite
 
EP
Thompson
 
KH
Cyclic oscillation of blood neutrophils in a patient with multiple myeloma.
Blood
55
1980
61
115
Gibson
 
CM
Gurney
 
CW
Gaston
 
EO
Simmons
 
EL
Cyclic erythropoiesis in the s1/s1d mouse.
Exp Hematol
12
1984
343
116
Gibson
 
CM
Gurney
 
CW
Simmons
 
EL
Gaston
 
EO
Further studies on cyclic erythropoiesis in mice.
Exp Hematol
13
1985
855
117
Gurney
 
CW
Simmons
 
EL
Gaston
 
EO
Cyclic erythropoiesis in w/wv mice following a single small dose of 89sr.
Exp Hematol
9
1981
118
118
Ranlov
 
P
Videbaek
 
A
Cyclic haemolytic anaemia synchronous with pel-ebstein fever in a case of Hodgkin’s disease.
Acta Med Scand
100
1963
429
119
Orr
 
JS
Kirk
 
J
Gray
 
KG
Anderson
 
JR
A study of the interdependence of red cell and bone marrow stem cell populations.
Br J Haematol
15
1968
23
120
Aranda
 
E
Dorantes
 
S
Garcia’s disease: Cyclic thrombocytopenic purpura in a child and abnormal platelet counts in his family.
Scand J Haematol
18
1977
39
121
Balduini
 
C
Stella
 
C
Rosti
 
V
Bertolino
 
G
Noris
 
P
Ascari
 
E
Acquired cyclic thrombocytopenia thrombocytosis with periodic defect of platelet function.
Br J Haematol
85
1993
718
122
Bernard
 
J
Caen
 
J
Purpura thrombopénique et megacaryocytopénie cycliques mensuels.
Nouv Rev Franc Hematol
2
1962
378
123
Brey
 
O
Garner
 
EPR
Wells
 
D
Cyclic thrombocytopenia associated with multiple antibodies.
Br Med J
3
1969
397
124
Caen
 
J
Meshaka
 
G
Larrieu
 
MJ
Bernard
 
J
Les purpuras thrombopéniques intermittents idiopathiques.
Semin Hop Paris
40
1964
276
125
Chintagumpala
 
MM
Hurwitz
 
RL
Moake
 
JL
Mahoney
 
DH
Steuber
 
CP
Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission.
J Pediatr
120
1992
49
126
Cohen
 
T
Cooney
 
DP
Cyclical thrombocytopenia: Case report and review of literature.
Scand J Haematol
16
1974
133
127
Dan
 
K
Inokuchi
 
K
An
 
E
Nomura
 
T
Cell mediated cyclic thrombocytopenia treated with azathioprine.
Br J Haematol
77
1991
365
128
Demmer
 
T
Morbus maculosus werlhofii in regelmassigen vierwochentlichen schuben bei einem 60 jahrigen mann, nebst untersuchungen uber die blutplattchen.
Folia Haematol
26
1920
74
129
Engstrom
 
K
Lundquist
 
A
Soderstrom
 
N
Periodic thrombocytopenia or tidal platelet dysgenesis in a man.
Scand J Haematol
3
1966
290
130
Goldschmidt
 
B
Fono
 
R
Cyclic fluctuations in platelet count, megakaryocyte maturation and thrombopoietin activity in cyanotic congenital heart disease.
Acta Paediatr Scand
61
1972
310
131
Lewis
 
ML
Cyclic thrombocytopenia: A thrombopoietin deficiency.
J Clin Pathol
27
1974
242
132
Skoog
 
WA
Lawrence
 
JS
Adams
 
WS
A metabolic study of a patient with idiopathic cyclical thrombocytopenic purpura.
Blood
12
1957
844
133
Tefferi
 
A
Solberg
 
LA
Petitt
 
RM
Willis
 
LG
Adult onset cyclic bicytopenia: A case report and review of treatment of cyclic hematopoiesis.
Am J Hematol
30
1989
181
134
Wasastjerna
 
C
Cyclic thrombocytopenia of acute type.
Scand J Haematol
4
1967
380
135
Wilkinson
 
T
Firkin
 
B
Idiopathic cyclical acute thrombocytopenic purpura.
Med J Aust
1
1966
217
136
Yanabu
 
M
Nomura
 
S
Fukuroi
 
T
Kawakatsu
 
T
Kido
 
H
Yamaguchi
 
K
Suzuki
 
M
Kokawa
 
T
Yasunaga
 
K
Periodic production of antiplatelet autoantibody directed against GP IIIa in cyclic thrombocytopenia.
Acta Haematol
89
1993
155
137
Morley
 
A
A platelet cycle in normal individuals.
Aust Ann Med
18
1969
127
138
von Schulthess
 
GK
Gessner
 
U
Oscillating platelet counts in healthy individuals: Experimental investigation and quantitative evaluation of thrombocytopoietic feedback control.
Scand J Haematol
36
1986
473
139
Dunn
 
CDR
Cyclic hematopoiesis: The biomathematics.
Exp Hematol
11
1983
779
140
Fisher
 
GV
An introduction to chaos theory and some haematological applications.
Comp Haematol Int
3
1993
43
141
Hodgson
 
G
Eskuche
 
I
Aplicacion de la teoria de control al estudio de la eritropoyesis.
Arch Biol Med Exp
3
1966
85
142
Loeffler
 
M
Pantel
 
K
A mathematical model of erythropoiesis suggests an altered plasma volume control as cause for anemia in aged mice.
Exp Gerontol
25
1990
483
143
Loeffler
 
M
Pantel
 
K
Wulff
 
H
Wichmann
 
HE
A mathematical model of erythropoiesis in mice and rats. Part I: Structure of the model.
Cell Tissue Kinet
22
1989
13
144
Vácha
 
J
Znojil
 
V
Application of a mathematical model of erythropoiesis to the process of recovery after acute x-irradiation of mice.
Biofizika
20
1975
872
145
Wichmann
 
HE
Loffler
 
M
Pantel
 
K
Wulff
 
H
A mathematical model of erythropoiesis in mice and rats. Part 2: Stimulated erythropoiesis.
Cell Tissue Kinet
22
1989
31
146
Wulf
 
H
Wichmann
 
HE
Pantel
 
K
Loeffler
 
M
A mathematical model of erythropoiesis in mice and rats. Part 3: Suppressed erythropoiesis.
Cell Tissue Kinet
22
1989
51
147
Znojil
 
V
Vácha
 
J
Mathematical model of the cytokinetics of erythropoiesis in the bone marrow and spleen of mice.
Biofizika
20
1975
661
148
Kirk
 
J
Orr
 
JS
Hop
 
CS
A mathematical analysis of red blood cell and bone marrow stem cell control mechanism.
Br J Haematol
15
1968
35
149
Kretchmar
 
AL
Erythropoietin: Hypothesis of action tested by analog computer.
Science
152
1966
367
150
Monot
 
C
Najean
 
Y
Dresch
 
C
Martin
 
J
Models of erythropoiesis and clinical diagnosis.
Math Biosci
27
1975
145
151
Mylrea
 
KC
Albrecht
 
PH
Mathematical analysis and digital simulation of the control of erythropoiesis.
J Theor Biol
33
1971
279
152
Wichmann
 
HE
Spechtmeyer
 
H
Gerecke
 
D
Gross
 
R
A mathematical model of erythropoiesis in man.
Lecture Notes in Biomathematics
11
1976
159
153
Bélair
 
J
Mackey
 
M
Mahaffy
 
JM
Age-structured and two-delay models for erythropoiesis.
Math Biosci
128
1995
317
154
Mackey
 
MC
Periodic auto-immune hemolytic anemia: An induced dynamical disease.
Bull Math Biol
41
1979
829
155
Mahaffy
 
JM
Bélair
 
J
Mackey
 
MC
Hematopoietic model with moving boundary condition and state dependent delay.
J Theor Biol
190
1998
135
156
Eller
 
J
Gyori
 
I
Zollei
 
J
Krizsa
 
F
Modelling thrombopoiesis regulation I: Model description and simulation results.
Comput Math Appl
14
1987
841
157
Kirk
 
J
Analysis by analogue and digital computers of the bone marrow stem cell and platelet control mechanisms, in Proceedings of Conference on Computers for Analysis and Control in Medical and Biological Research.
1971
120
IEE
UK
158
Gyori
 
I
Eller
 
J
Modelling thrombopoiesis regulation II: Mathematical investigation of the model.
Comput Math Appl
14
1987
849
159
Wichmann
 
HE
Gerhardts
 
MD
Spechtmeyer
 
H
Gross
 
R
A mathematical model of thrombopoiesis in rat.
Cell Tissue Kinet
12
1979
551
160
Bélair
 
J
Mackey
 
M
A model for the regulation of mammalian platelet.
Ann NY Acad Sci
504
1987
280
161
Blumenson
 
LE
A comprehensive modeling procedure for the human granulopoietic system: Over-all view and summary of data.
Blood
42
1973
303
162
Blumenson
 
LE
A comprehensive modeling procedure for the human granulopoietic system: Detailed description and application to cancer chemotherapy.
Math Biosci
26
1975
217
163
Fokas
 
AS
Keller
 
JB
Clarkson
 
BD
Mathematical model of granulcytopoiesis and chronic myelogenous leukemia.
Cancer Res
51
1991
2084
164
Rubinow
 
SI
A simple model of a steady state differentiating cell system.
J Cell Biol
43
1969
32
165
Rubinow
 
SI
Lebowitz
 
JL
Sapse
 
AM
Parameterization of in vivo leukemic cell populations.
Biophys J
11
1971
175
166
Rubinow
 
SI
Lebowitz
 
JL
A mathematical model of neutrophil production and control in normal man.
J Math Biol
1
1975
187
167
Rubinow
 
SI
Lebowitz
 
JL
A mathematical model of the acute myeloblastic leukemia.
Biophys J
16
1976
897
168
Rubinow
 
SI
Lebowitz
 
JL
A mathematical model of the chemotherapeutic treatment of acute myeloblastic leukemia.
Biophys J
16
1976
1257
169
Smeby
 
W
Benestad
 
HB
Simulation of murine granulopoiesis.
Blut
41
1980
47
170
Steinbach
 
KH
Raffler
 
H
Pabst
 
G
Fliedner
 
TM
A mathematical model of canine granulocytopoiesis.
J Math Biol
10
1980
1
171
Wheldon
 
TE
Mathematical models of oscillatory blood cell production.
Math Biosci
24
1975
289
172
Wichmann
 
HE
Loffler
 
M
Mathematical Modeling of Cell Proliferation: Stem Cell Regulation in Hemopoiesis.
1988
CRC
Boca Raton, FL
173
Kazarinoff
 
ND
van den Driessche
 
P
Control of oscillations in hematopoiesis.
Science
203
1979
1348
174
King-Smith
 
EA
Morley
 
A
Computer simulation of granulopoiesis: Normal and impaired granulopoiesis.
Blood
36
1970
254
175
MacDonald
 
N
Cyclical neutropenia: Models with two cell types and two time lags
Valleron
 
AJ
Macdonald
 
PDM
Biomathematics and Cell Kinetics.
1978
287
Elsevier/North-Holland
Amsterdam, The Netherlands
176
Morley
 
A
Periodic diseases, physiological rhythms and feedback control—A hypothesis.
Aust Ann Med
3
1970
244
177
Reeve
 
J
An analogue model of granulopoiesis for the analysis of isotopic and other data obtained in the non-steady state.
Br J Haematol
25
1973
15
178
von Schulthess
 
GK
Mazer
 
NA
Cyclic neutropenia (CN): A clue to the control of granulopoiesis.
Blood
59
1982
27
179
Kolesov
 
YS
Mathematical modeling of the production of white blood cells
Marchuk
 
G
Belykh
 
LN
Mathematical Modeling in Immunology and Medicine.
1983
211
North-Holland
Amsterdam, The Netherlands
180
Schmitz S: Ein mathematisches Modell der zyklischen Haemopoese. PhD thesis, Koln, Germany, Universitat Koln, 1988
181
Schmitz
 
S
Franke
 
H
Brusis
 
J
Wichmann
 
HE
Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis.
Exp Hematol
21
1993
755
182
Schmitz
 
S
Franke
 
H
Loeffler
 
M
Wichmann
 
HE
Diehl
 
V
Reduced variance of bone-marrow transit time of granulopoiesis: A possible pathomechanism of human cyclic neutropenia.
Cell Prolif
27
1994
655
183
Schmitz
 
S
Franke
 
H
Wichmann
 
HE
Diehl
 
V
The effect of continuous G-CSF application in human cyclic neutropenia: A model analysis.
Br J Haematol
90
1995
41
184
Schmitz
 
S
Loeffler
 
M
Jones
 
JB
Lange
 
RD
Wichmann
 
HE
Synchrony of bone marrow proliferation and maturation as the origin of cyclic haemopoiesis.
Cell Tissue Kinet
23
1990
425
185
Wichmann
 
HE
Loeffler
 
M
Schmitz
 
S
A concept of hemopoietic regulation and its biomathematical realization.
Blood Cells
14
1988
411
186
Hearn
 
T
Haurie
 
C
Mackey
 
MC
Cyclical neutropenia and the peripherial control of white blood cell production.
J Theor Biol
192
1998
167
187
Wheldon
 
TE
Kirk
 
J
Finlay
 
HM
Cyclical granulopoiesis in chronic granulocytic leukemia: A simulation study.
Blood
43
1974
379
188
Mackey
 
MC
Glass
 
L
Oscillations and chaos in physiological control systems.
Science
197
1977
287
189
Perry
 
S
Moxley
 
JH
Weiss
 
GH
Zelen
 
M
Studies of leukocyte kinetics by liquid scintillation counting in normal individuals and in patients with chronic myelogenous leukemia.
J Clin Invest
45
1966
1388
190
Zimmerman
 
TS
Godwin
 
H
Perry
 
S
Studies of leukocyte kinetics in chronic lymphocytic leukemia.
Blood
31
1968
277
191
Mackey
 
MC
A unified hypothesis for the origin of aplastic anemia and periodic haematopoiesis.
Blood
51
1978
941
192
Milton
 
JG
Mackey
 
MC
Periodic haematological diseases: Mystical entities or dynamical disorders?
J R Coll Phys Lond
23
1989
236
193
Mackey
 
MC
Mathematical models of hematopoietic cell replication control
Othmer
 
HG
Adler
 
FR
Lewis
 
MA
Dallon
 
JC
The Art of Mathematical Modeling: Case Studies in Ecology, Physiology and Biofluids.
1966
149
Prentice Hall
New York, NY
194
Good
 
PI
Alternative mechanisms for homeostatic regulation of mammalian cell populations.
J Theor Biol
40
1973
543
195
Grudinin
 
MM
Klochko
 
AV
Lukshin
 
YV
Klochko
 
EV
Study of the kinetics of the functioning of a population of haemopoietic stem cells using analogue modeling devices.
Biophysics
23
1978
343
196
Gruzdev
 
GP
Monichev
 
Y
Model of the regulation of the rate of multiplication of the stem cells of the bone marrow.
Biophysics
20
1975
308
197
Nazarenko
 
VG
Influence of delay on auto-oscillations in cell populations.
Biophysics
21
1997
352
198
Nazarenko
 
VG
Modification of the model of a cell population depressing its mitotic activity.
Biophysics
23
1978
337
199
Newton
 
CM
Computer simulation of stem cell kinetics.
Bull Math Biophys
27
1965
275
200
Rotenberg
 
M
Stability analysis of the two compartment model of cell proliferation.
J Theor Biol
77
1979
51
201
Rotenberg
 
M
Theory of distributed quiescent state in the cell cycle.
J Theor Biol
96
1982
495
202
Rotenberg
 
M
Transport theory for growing cell populations.
J Cell Biol
103
1983
181
203
Necas
 
E
Hauser
 
F
Simulation of CFU-S kinetics after irradiation.
Cell Tissue Kinet
21
1988
81
204
Necas
 
E
Znojil
 
V
Bone marrow response to single small doses of irradiation: Implications for stem cell functional organization.
Exp Hematol
16
1988
871
205
Necas
 
E
Znojil
 
V
Non-circadian rhythm in proliferation of haematopoietic stem cells.
Cell Tissue Kinet
21
1988
73
206
Maity
 
A
McKenna
 
WG
Muschel
 
RJ
The molecular basis for cell cycle delays following ionizing radiation: A review.
Radiother Oncol
31
1994
1
Sign in via your Institution